The key difference
Phentermine is a sympathomimetic amine — a stimulant-class appetite suppressant. Wegovy (semaglutide) is a GLP-1 receptor agonist. They work through completely different biological pathways.
Phentermine increases norepinephrine to suppress appetite and boost energy. Wegovy mimics a natural gut hormone to reduce appetite, slow digestion, and improve metabolic signaling.
This difference affects everything — efficacy, side effects, cost, and treatment duration. Phentermine has been available since 1959 and is one of the most prescribed weight loss medications in the United States. Wegovy received FDA approval in 2021 and represents a newer class of medications that has changed how weight loss is treated.
Head-to-head comparison
| Feature | Phentermine | Wegovy |
|---|---|---|
| Drug class | Sympathomimetic amine | GLP-1 receptor agonist |
| Active ingredient | Phentermine HCl | Semaglutide |
| How taken | Daily oral tablet | Weekly subcutaneous injection |
| FDA approved for | Short-term weight management (1959) | Chronic weight management (2021) |
| Avg weight loss | 5–10% body weight (12 weeks) | ~15% body weight (68 weeks) |
| CV benefit | Not established | FDA-approved to reduce MACE risk |
| Duration of use | Short-term (typically 12 weeks) | Long-term (chronic) |
| Insurance coverage | Nearly universal | Varies; many plans cover it |
| Typical cost | low monthly generic pricing (generic) | Insurance or insurance or higher out-of-pocket pricing |
| Main side effects | Dry mouth, insomnia, elevated HR | Nausea, diarrhea, constipation |
| Controlled substance | Yes (Schedule IV) | No |
| Manufacturer | Various (generic) | Novo Nordisk |
When phentermine may be the right choice
- You’re new to weight loss medication and want a first-line treatment
- Your insurance requires step therapy (trying phentermine) before approving a GLP-1
- Cost is a primary concern and you don’t have GLP-1 coverage
- You prefer taking a daily oral pill over a weekly injection
- You want a short-term kickstart before transitioning to long-term treatment
Phentermine is the most commonly prescribed weight loss medication in the U.S. for good reason. It’s affordable, widely covered by insurance, and effective for short-term weight management. Many patients lose meaningful weight on phentermine alone.
When Wegovy may be the right choice
- You’re seeking maximum weight loss (15%+ of body weight)
- You have cardiovascular risk factors and would benefit from the SELECT trial cardiovascular protection
- You’re ready for long-term medication management
- You’ve tried phentermine and need more effective treatment
Wegovy produces significantly more weight loss than phentermine and is approved for chronic (long-term) use. The SELECT trial demonstrated that semaglutide reduces the risk of major cardiovascular events in patients with established heart disease who have obesity or are overweight — a benefit phentermine has not been shown to provide.
Many insurers require phentermine before approving Wegovy. This doesn’t mean phentermine is inferior — it’s a different tool. Some patients lose meaningful weight on phentermine alone. Others use it to satisfy step therapy requirements while building the documentation needed for GLP-1 approval. PEAK manages this entire process.
Can you take both?
Yes, in some cases. Phentermine and Wegovy work through different mechanisms, so combination therapy can be clinically appropriate. Some clinicians add phentermine during the GLP-1 dose-escalation phase or when a patient hits a weight loss plateau.
Because they target different pathways — phentermine increases norepinephrine while Wegovy acts on GLP-1 receptors — the combination can provide complementary effects without the overlapping risk you’d see from combining two GLP-1 medications.
For a deeper look at how these medications work together, see our guide on taking phentermine and Wegovy together.
The right medication isn’t always the newest one. It’s the one that fits your health, your insurance, and your goals.
How PEAK handles this decision
PEAK prescribes both medications and helps patients find the right fit. You may start with phentermine and transition to Wegovy, use Wegovy from the beginning, or use both together. The decision is based on your health history, insurance situation, and goals.
This is not a one-size-fits-all decision. Some patients do exceptionally well on phentermine alone. Others need the greater efficacy of a GLP-1. Many use phentermine as a bridge while we work through the prior authorization process for Wegovy or another GLP-1 medication.
Whatever your path, we manage the clinical decisions, the insurance documentation, and the ongoing monitoring so you can focus on your results.
Boxed warning — thyroid C-cell tumors: GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) carry an FDA boxed warning for thyroid C-cell tumors observed in rodent studies. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Tell your provider immediately if you notice a lump in your neck, difficulty swallowing, or persistent hoarseness.
